FDA Approves Imlunestrant for Advanced Breast Cancer with ESR1 Mutations
The Food and Drug Administration (FDA) has granted approval for imlunestrant, an oral medication developed by Eli Lilly and Company, to treat adults diagnosed with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), ESR1-mutated advanced or metastatic breast cancer. This approval applies to patients whose cancer has progressed after receiving at least one prior endocrine therapy.
This decision is based on the positive results observed in a phase 3 clinical trial involving 874 patients. Specifically,among the 256 patients identified with ESR1 mutations,imlunestrant demonstrated a median progression-free survival of 5.5 months, a notable improvement compared to the 3.8 months observed in patients receiving standard endocrine therapies, as detailed in the FDA’s announcement on September 25, 2023. FDA approval News Release
Furthermore, the trial indicated a higher objective response rate with imlunestrant, registering at 14.3%, in contrast to the 7.7% response rate seen in the comparison group. FDA Approval News Release Imlunestrant functions as an oral estrogen receptor antagonist, offering a new treatment option for a challenging subset of breast cancer patients.
Analysis & Strategy Keywords:
* Primary Topic: FDA Approval of Imlunestrant for Breast Cancer
* Primary Keyword: Imlunestrant
* Secondary Keywords: breast Cancer, ESR1 Mutation, Endocrine Therapy, FDA Approval, Metastatic Breast Cancer, Eli lilly, Progression-Free Survival, HER2-Negative, ER-Positive.